Table 1.
Summary of number of drug candidates. (A) Drugs for high-glycolysis mCRPC; (B) dual-effect drugs.
| (A) Drugs Showing High Efficacy in High-Glycolysis mCRPC Patients (DrugHG) | ||||
| Clinical study | SU2C/EC | SU2C/WC | SU2C/EC | SU2C/WC |
| Training Drug database | CTRPv2 | CTRPv2 | PRISM | PRISM |
| Drugs predicted to show high efficacy in high-glycolysis mCRPC patients | 41 | 5 | 260 | 67 |
| DrugHG (SU2C/EC ∩ SU2C/WC) |
4 | 54 | ||
| DrugHG in primary MOA #,* |
0 | 9 & | ||
| (B) Dual-Effect Drugs (DrugDE) | ||||
| Clinical study | SU2C/EC | SU2C/WC | SU2C/EC | SU2C/WC |
| Training drug database | CTRPv2 | CTRPv2 | PRISM | PRISM |
| Drugs for high glycolysis mCRPC (G) | 41 | 5 | 260 | 67 |
| Drugs for high-OXPHOS mCRPC (O) | 80 | 59 | 530 | 492 |
| DrugDE (G ∩ O) | 13 | 0 | 156 | 27 |
| DrugDE (SU2C/EC ∩ SU2C/WC) |
0 | 19 | ||
Notes: #: Primary MOA is characterized by a MOA that appeared at least twice across these 54 DrugHG from PRISM. *: Primary MOAs include aurora kinase inhibitors, CDK inhibitors, EGFR inhibitors, HSP inhibitors, mTOR inhibitors, and topoisomerase inhibitors. &: Drugs were obtained from overlapping the top 50% significant drugs identified from SU2C/EC and SU2C/WC studies. Abbreviations: mCRPC: metastatic castration-resistant prostate cancer; DrugHG: drugs for high-glycolysis mCRPC; DrugDE: dual-effect drugs; SU2C/EC: Standard Up to Cancer East Coast; SU2C/WC: Standard Up to Cancer West Coast; CTRPv2: Cancer Therapeutics Response Portal Version 2; PRISM: Profiling Relative Inhibition Simultaneously in Mixtures; MOA: mechanism of action; OXPHOS: oxidative phosphorylation.